Sphaera Pharma Research And Development Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 17-07-2024
- Paid Up Capital ₹ 0.20 M
as on 17-07-2024
- Company Age 16 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.19 Cr
as on 17-07-2024
- Revenue -64.81%
(FY 2023)
- Profit -18370.60%
(FY 2023)
- Ebitda -132.57%
(FY 2023)
- Net Worth -41.22%
(FY 2023)
- Total Assets -88.12%
(FY 2023)
About Sphaera Pharma Research And Development
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M.
The company has closed loans amounting to ₹1.19 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Abhinav Dhandia and Ashish Dugar serve as directors at the Company.
- CIN/LLPIN
U24232DL2008PTC224719
- Company No.
224719
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Nov 2008
- Date of AGM
26 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Sphaera Pharma Research And Development?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhinav Dhandia  | Director | 28-Nov-2008 | Current |
| Ashish Dugar | Director | 02-Dec-2022 | Current |
Financial Performance of Sphaera Pharma Research And Development.
Sphaera Pharma Research And Development Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 64.81% decrease. The company also saw a substantial fall in profitability, with a 18370.6% decrease in profit. The company's net worth observed a substantial decline by a decrease of 41.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sphaera Pharma Research And Development?
In 2023, Sphaera Pharma Research And Development had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sphaera Pharma Private LimitedActive 17 years 1 monthAbhinav Dhandia and Ashish Dugar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Biotechnology Industry Research Assistance Council Creation Date: 16 Dec 2011 | ₹1.19 Cr | Satisfied |
How Many Employees Work at Sphaera Pharma Research And Development?
Unlock and access historical data on people associated with Sphaera Pharma Research And Development, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sphaera Pharma Research And Development, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sphaera Pharma Research And Development's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
